GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill

British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.